Treprostinil SR is under clinical development by Camurus and currently in Phase II for Raynauds Disease. According to GlobalData, Phase II drugs for Raynauds Disease does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Treprostinil SR LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Treprostinil SR overview
Treprostinil (CAM-2043) is under development for the treatment of pulmonary arterial hypertension and Raynaud’s disease secondary to systemic sclerosis. It is a sustained release injectable formulation and administered subcutaneously. It acts by targeting prostacyclin receptor. The drug candidate is a once-weekly liquid crystal gel formulation developed based on FluidCrystal injectable depot technology.
See Also:
Camurus overview
Camurus, a subsidiary of Sandberg Development AB, is a pharmaceutical company. It carries out development and commercialization of treatments for the patients suffering from chronic diseases. The company’s major products include CAM2038 to treat chronic pain; CAM2029 to treat acromegaly, GEP-NET and PLD; CAM4072 to treat genetic obesity disorders; CAM2032 to treat Prostate cancer; CAM2043 to treat pulmonary arterial hypertension and raynaud’s phenomenon; CAM4071 to treat endocrine disorders; buvidal drug candidates. It markets drugs under the brand name of Episil, FluidCrystal. The company has developmental and commercial collaborations with biotechnology and pharmaceutical companies for product development. Camurus is headquartered in Lund, Sweden.
For a complete picture of Treprostinil SR’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
